Online citations, reference lists, and bibliographies.

Precocious Puberty Therapeutic Management: GnRH Analogs Treatment

C. Bouvattier
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
GnRH analog therapy is an effective treatment for central precocious puberty. The therapeutic management of central precocious puberty should be discussed on clinical criteria (rapidly progressive puberty, advance bone age), biological criteria (LH, inhibin B, estradiol), and ultrasound criteria (uterine length, ovarian volume). The optimal timing of treatment discontinuation has not been clearly evaluated. The average age of discontinuation is around 11 years, the physiological age of puberty in girls. Menarche occurs 12–18 months after the end of treatment. Clinical pubertal signs reappear a few months after the end of the treatment. Compromise of adult height, early menarche, and social and behavioral implications is often a concern for these patients.
This paper references
Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
E. Neely (1992)
A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty.
K. L. Eckert (1996)
The use of GnRH agonists in precocious puberty.
D. Mul (2008)
Secondary sexual characteristics in children with cerebral palsy and moderate to severe motor impairment: a cross-sectional survey.
G. Worley (2002)
Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
J. Carel (1999)
Precocious Puberty in Adolescent Girls: A Biomarker of Later Psychosocial Adjustment Problems
L. Tremblay (2005)
Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
M. Palmert (1999)
Effect of Gonadotropin-Releasing Hormone Agonist Treatment in Boys with Central Precocious Puberty: Final Height Results
D. Mul (2002)
Treatment of central precocious puberty.
C. Partsch (2002)
Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty.
S. S. Mogensen (2011)
Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
T. Arrigo (1999)
Effect of Treatment with Cyproterone Acetate on Uterine Bleeding at the Beginning of GnRH Analogue Therapy in Girls with Idiopathic Central Precocious Puberty
S. Seminara (2010)
Precocious puberty and statural growth.
Jean-Claude Carel (2004)
Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children.
E. M. Resende (2007)
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Jean-Claude Carel (2006)
Local reactions to depot leuprolide therapy for central precocious puberty.
P. Manasco (1993)
Pelvic ultrasound and color Doppler findings in different isosexual precocities.
C. Battaglia (2003)
Very long-term follow-up of girls with early and late menarche.
Thérese Johansson (2005)
Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
L. Lazar (2001)
Suppression of menstruation in adolescents with severe learning disabilities
A. Albanese (2007)
Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function
S. Heger (2006)
The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
M. A. Magiakou (2010)
Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities.
M. Chalumeau (2002)
Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years.
D. Paul (1995)
Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
Jean-Claude Carel (2002)
Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy.
P. Feuillan (2000)
Idiopathic central precocious puberty in girls: presentation factors
Géraldine Prété (2008)
Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.
K. Klein (2001)
Selecting girls with precocious puberty for brain imaging: validation of European evidence-based diagnosis rule.
M. Chalumeau (2003)
Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration.
L. Soriano-Guillén (2010)
Outcomes of early pubertal timing in young women: a prospective population-based study.
William E. Copeland (2010)
Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche.
L. de Vries (2006)
Prevalence and Incidence of Precocious Pubertal Development in Denmark: An Epidemiologic Study Based on National Registries
G. Teilmann (2005)
Serum Inhibin A and Inhibin B in Central Precocious Puberty before and during Treatment with GnRH Agonists
A. Sehested (2000)
Precocious puberty.
Jean-Claude Carel (1986)
Treatment and outcomes of precocious puberty: an update.
J. Fuqua (2013)
Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
Jean-Claude Carel (2009)
Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.
S. Bertelloni (2008)
Pelvic ultrasonography: Early differentiation between isolated premature thelarche and central precocious puberty
H. P. Haber (2005)
Etiology of Central Precocious Puberty in Males: The Results of the Italian Study Group for Physiopathology of Puberty
V. De Sanctis (2000)
Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
C. Hagen (2012)
Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study.
C. Bouvattier (1999)
Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity.
L. Lazar (2007)
Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty.
E. Neely (1995)
Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients.
M. Palmert (1999)
Pharmacokinetics and Pharmacodynamics of GnRH Agonists: Clinical Implications in Pediatrics
N. Lahlou (2000)
Central precocious puberty: clinical and laboratory features *
W. Chemaitilly (2001)
Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report.
F. Comite (1981)
Precocious puberty: who has it? Who should be treated?
K. Klein (1999)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar